Cellular Mechanisms of Multiple Myeloma Bone Disease

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy

(2012) E. Terpos et al.   ANNALS OF ONCOLOGY

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

(2012) N Giuliani et al.   LEUKEMIA

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

(2011) Giacomina Brunetti et al.   Annals of the New York Academy of Sciences

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up

(2011) Bo Björkstrand et al.   JOURNAL OF CLINICAL ONCOLOGY

The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3

(2010) Giacomina Brunetti et al.   Annals of the New York Academy of Sciences

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

(2010) K. Noonan et al.   BLOOD

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

(2010) R. H. Prabhala et al.   BLOOD

RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II

(2010) F. Hemingway et al.   BONE

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

(2010) Andrew D Chantry et al.   JOURNAL OF BONE AND MINERAL RESEARCH

TNF-α's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression

(2010) Olfa Ghali et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia

(2009) D. C. Rees et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY

The significance of monoclonal gammopathy of undetermined significance

(2009) R. A. Kyle et al.   HAEMATOLOGICA

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

(2009) S Colucci et al.   LEUKEMIA

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

(2008) K. M. Dhodapkar et al.   BLOOD

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

(2008) Deborah J Heath et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

(2008) Mehmet Sonmez et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA

A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

(2008) R. S. Pearsall et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

(2008) Y. Onishi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA